CollPlant Successfully Bio-Prints 200cc Commercial-Size Regenerative Breast Implants and Reports Additional Positive Pre-Clinical Data
CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its ...
CollPlant Biotechnologies First Quarter 2024 Earnings: Misses Expectations
Analysts Offer Insights on Healthcare Companies: Aura Biosciences Inc (AURA), Collplant Holdings (CLGN) and Zimmer Biomet Holdings (ZBH)
Earnings Call Summary | Collplant(CLGN.US) Q1 2024 Earnings Conference
The following is a summary of the CollPlant Biotechnologies Ltd. (CLGN) Q1 2024 Earnings Call Transcript:Financial Performance:CollPlant reported a decline in Q1 2024 revenue to $98,000, primarily due
CollPlant Biotechnologies Ltd. (CLGN) Q1 2024 Earnings Call Transcript
CollPlant Biotechnologies Ltd. (CLGN) Q1 2024 Earnings Call Transcript
CollPlant Highlights Innovation Amidst Q1 Financials
Collplant | 6-K: Report of foreign private issuer (related to financial reporting)
Earnings Flash (CLGN) COLLPLANT Reports Q1 Revenue $98,000, Vs. Street Est of $650,000
07:03 AM EDT, 05/29/2024 (MT Newswires) -- Earnings Flash (CLGN) COLLPLANT Reports Q1 Revenue $98,000, vs. Street Est of $650,000
CollPlant Biotechnologies Q1 Adj $(0.35), Inline, Sales $98.00K Miss $600.00K Estimate
CollPlant Biotechnologies (NASDAQ:CLGN) reported quarterly losses of $(0.35) per share which met the analyst consensus estimate. This is a 20.69 percent decrease over losses of $(0.29) per share from
Press Release: CollPlant Biotechnologies Announces First Quarter Financial Results For 2024 and Provides Corporate Update
CollPlant Biotechnologies Announces First Quarter Financial Results For 2024 and Provides Corporate Update PR Newswire REHOVOT, Israel, May 29, 2024 Additional large-animal study with commercial-si
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2024 FIRST QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION
CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its ...
CollPlant Biotechnologies (NASDAQ:CLGN) Is In A Strong Position To Grow Its Business
CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Q4 2023 Earnings Call Transcript
CollPlant Biotechnologies Ltd (CLGN) Q4 2023 Earnings Call Transcript Highlights: A Year of ...
Buy Rating Affirmed for Collplant Holdings on Strong Financials and Promising Product Pipeline Advancements
Earnings Call Summary | Collplant(CLGN.US) Q4 2023 Earnings Conference
The following is a summary of the CollPlant Biotechnologies Ltd. (CLGN) Q4 2023 Earnings Call Transcript:Financial Performance:CollPlant reported Q4 2023 revenues of $299,000, an increase from $58,000
CollPlant Biotechnologies' Strong Financial and R&D Progress
CollPlant Biotechnologies Q4 Adj EPS $(0.35) Misses $(0.07) Estimate, Sales $299.00K Miss $8.56M Estimate
CollPlant Biotechnologies (NASDAQ:CLGN) reported quarterly Adj losses of $(0.35) per share which missed the analyst consensus estimate of $(0.07) by 400 percent. This is unchanged from the same period
Collplant Biotechnologies FY23 Loss/Shr 62c >CLGN
Collplant Biotechnologies FY23 Loss/Shr 62c >CLGN
Express News | CollPlant Biotechnologies Reports 2023 GAAP Revenues Of $11M, Up By $10.7M From Last Year
No Data